Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes

  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Luna Salva, Noemí de|||0000-0002-4342-794X
Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of patients with dysferlinopathy is characterized by the presence of inflammatory infiltrates. Studies in the muscle of both human and mouse models of dysferlinopathy suggest dysferlin deficient muscle plays a role in this inflammation by releasing thrombospondin-1. It has also been reported that vitamin D3 treatment enhances dysferlin expression. The ubiquitin-proteasome system recognizes and removes proteins that fail to fold or assemble properly and previous studies suggest that its inhibition could have a therapeutic effect in muscle dystrophies. Here we assessed whether inhibition of the ubiquitin proteasome system prevented degradation of dysferlin in immortalized myoblasts from a patients with two missense mutations in exon 44. To assess proteasome inhibition we treated dysferlin deficient myotubes with EB1089, a vitamin D3 analog, oprozomib and ixazomib. Western blot was performed to analyze the effect of these treatments on the recovery of dysferlin and myogenin expression. TSP-1 was quantified using the enzyme-linked immunosorbent assay to analyze the effect of these drugs on its release. A membrane repair assay was designed to assess the ability of treated myotubes to recover after membrane injury and fusion index was also measured with the different treatments. Data were analyzed using a one-way ANOVA test followed by Tukey post hoc test and analysis of variance. A p ≤ 0.05 was considered statistically significant. Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and myogenin expression. Furthermore, EB1089 and proteasome inhibitors reduced the release of TSP-1 in myotubes. However, no effect was observed on the repair of muscle membrane after injury. Our findings indicate that the ubiquitin-proteasome system might not be the main mechanism of mutant dysferlin degradation. However, its inhibition could help to improve muscle inflammation by reducing TSP-1 release. The online version contains supplementary material available at 10.1186/s12891-020-03756-7.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies

  • Alonso-Jiménez, Alicia|||0000-0002-2200-9255
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • García, Carme
  • Montiel Morillo, Elena
  • Belmonte Jimeno, Izaskun|||0000-0003-0930-6586
  • Pedrosa Hernández, Irene
  • Segovia, Sonia
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Nascimento, Andrés
  • Llauger, Jaume|||0000-0002-3744-3257
  • Nuñez Peralta, Claudia Alejandra|||0000-0002-3235-0799
  • Montesinos, Paula|||0000-0001-6944-7730
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Introduction: Duchenne (DMD) and Becker (BMD) muscular dystrophy are X-linked muscular disorders produced by mutations in the DMD gene which encodes the protein dystrophin. Both diseases are characterized by progressive involvement of skeletal, cardiac, and respiratory muscles. As new treatment strategies become available, reliable biomarkers and outcome measures that can monitor disease progression are needed for clinical trials. Methods: We collected clinical and functional data and blood samples from 19 DMD patients, 13 BMD patients, and 66 healthy controls (8 pediatric and 58 adult controls), and blood samples from 15 patients with dysferlinopathy (DYSF) and studied the serum concentration of 4 growth factors involved in the process of muscle fibrosis. We correlated the serum concentration of these growth factors with several muscle function tests, spirometry results and fat fraction identified by quantitative Dixon muscle MRI. Results: We found significant differences in the serum concentration of Platelet Derived Growth Factor-AA (PDGF-AA) between DMD patients and pediatric controls, in Connective Tissue Growth Factor (CTGF) between BMD patients and adult controls, and in and Transforming Growth Factor- β1 (TGF-β1) between BMD and DYSF patients. PDGF-AA showed a good correlation with several muscle function tests for both DMD and BMD patients and with thigh fat fraction in BMD patients. Moreover, PDGF-AA levels were increased in muscle biopsies of patients with DMD and BMD as was demonstrated by immunohistochemistry and Real-Time PCR studies. Conclusion: Our study suggests that PDGF-AA should be further investigated in a larger cohort of DMD and BMD patients because it might be a good biomarker candidate to monitor the progression of these diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autoantibody screening in Guillain-Barré syndrome

  • Lleixà, Cinta|||0000-0002-9971-0584
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Franco Leyva, Teresa|||0000-0002-0250-0274
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Suárez Calvet, Xavier|||0000-0002-5314-6607
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Homedes, C.
  • Gutiérrez-Gutiérrez, Gerardo
  • Jimeno-Montero, M. C.
  • Berciano, José|||0000-0001-9261-9748
  • Sedano-Tous, M. J.
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Pardo, Julio|||0000-0001-8807-1310
  • Márquez-Infante, C.
  • Rojas-Marcos, I.|||0000-0003-4142-4283
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Martínez Hernández, Eugenia
  • Morís, Germán|||0000-0001-7608-2194
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice

  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Badimon, Lina|||0000-0002-9162-2459
  • Wollin, Lutz|||0000-0002-3617-5772
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
Sarcoglycanopathies are a group of recessive limb-girdle muscular dystrophies, characterized by progressive muscle weakness. Sarcoglycan deficiency produces instability of the sarcolemma during muscle contraction, leading to continuous muscle fiber injury eventually producing fiber loss and replacement by fibro-adipose tissue. Therapeutic strategies aiming to reduce fibro-adipose expansion could be effective in muscular dystrophies. We report the positive effect of nintedanib in a murine model of alpha-sarcoglycanopathy. We treated 14 Sgca mice, six weeks old, with nintedanib 50 mg/kg every 12 h for 10 weeks and compared muscle function and histology with 14 Sgca mice treated with vehicle and six wild-type littermate mice. Muscle function was assessed using a treadmill and grip strength. A cardiac evaluation was performed by echocardiography and histological study. Structural analysis of the muscles, including a detailed study of the fibrotic and inflammatory processes, was performed using conventional staining and immunofluorescence. In addition, proteomics and transcriptomics studies were carried out. Nintedanib was well tolerated by the animals treated, although we observed weight loss. Sgca mice treated with nintedanib covered a longer distance on the treadmill, compared with non-treated Sgca mice, and showed higher strength in the grip test. Moreover, nintedanib improved the muscle architecture of treated mice, reducing the degenerative area and the fibrotic reaction that was associated with a reversion of the cytokine expression profile. Nintedanib improved muscle function and muscle architecture by reducing muscle fibrosis and degeneration and reverting the chronic inflammatory environment suggesting that it could be a useful therapy for patients with alpha-sarcoglycanopathy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Isolation of human fibroadipogenic progenitors and satellite cells from frozen muscle biopsies

  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Lleixà, Cinta|||0000-0002-9971-0584
  • López-Fernández, Susana
  • Pons, Gemma|||0000-0001-8803-5432
  • Soria, L.
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, V.
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Jaiswal, JK.|||0000-0002-5992-5185
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Skeletal muscle contains multiple cell types that work together to maintain tissue homeostasis. Among these, satellite cells (SC) and fibroadipogenic progenitors cells (FAPs) are the two main stem cell pools. Studies of these cells using animal models have shown the importance of interactions between these cells in repair of healthy muscle, and degeneration of dystrophic muscle. Due to the unavailability of fresh patient muscle biopsies, similar analysis of interactions between human FAPs and SCs is limited especially among the muscular dystrophy patients. To address this issue here we describe a method that allows the use of frozen human skeletal muscle biopsies to simultaneously isolate and grow SCs and FAPs from healthy or dystrophic patients. We show that while the purified SCs differentiate into mature myotubes, purified FAPs can differentiate into adipocytes or fibroblasts demonstrating their multipotency. We find that these FAPs can be immortalized and the immortalized FAPs (iFAPs) retain their multipotency. These approaches open the door for carrying out personalized analysis of patient FAPs and interactions with the SCs that lead to muscle loss.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Rajabally, Yusuf
  • Scotton, Sangeeta
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Baars, Adája Elisabeth|||0000-0001-7842-0871
  • Cortese, Andrea
  • Vegezzi, Elisa|||0000-0001-8776-6831
  • Höftberger, Romana|||0000-0002-5769-1100
  • Zimprich, Fritz|||0000-0002-6998-5480
  • Roesler, Cornelia
  • Nobile-Orazio, Eduardo|||0000-0003-2624-8138
  • Liberatore, Giuseppe|||0000-0003-2666-1678
  • Hiew, Fu Liong|||0000-0002-4708-3734
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Carvajal, Alejandra
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Usón-Martín, Mercedes
  • Albertí, Olalla
  • López Pérez, María Ángeles
  • Márquez, Fabian
  • Pardo-Fernández, Julio
  • Muñoz-Delgado, Laura|||0000-0002-8818-1824
  • Cabrera-Serrano, Macarena|||0000-0003-3109-6095
  • Ortiz-Castellon, Nicolau|||0000-0001-9544-2642
  • Bartolomé, Manuel
  • Duman, Özgür
  • Bril, Vera
  • Segura-Chávez, Darwin
  • Pitarokoili, Kalliopi
  • Steen, Claudia
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN).MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up.ResultsForty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients.DiscussionAnti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases.Classification of EvidenceThis study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab.